GTx forced to stop development of Capesaris (GTx-758)

The US Food & Drug Administration (FDA) has advised GTx to stop development of GTx-758 (also known as Capesaris), its oral drug intended for the treatment of men with advanced prostate cancer, after it became apparent that there was an increase in risk for blood clots in men taking active drug compared to those being [...]

Korean study says that HIFU “does not provide effective oncologic outcomes”

A new paper by clinical researchers in Korea has concluded that treatment with high-intensity focused ultrasound (HIFU) “does not provide effective oncologic outcomes even in low risk patients with prostate cancer as well as in the intermediate or high risk groups,” but does have a low associated incidence of treatment complications.

Brachytherapy: is it really “better” as a first-line treatment for low- and intermediate-risk prostate cancer?

An analysis of data on treatment of nearly 137,500 men treated for prostate cancer between 1991 and 2007 has suggested that permanent seed brachytherapy may be safer, less costly, and at least as effective as any other widely available form of first-line therapy for men with low- and intermediate-risk prostate cancer.

New data on risks of prostate biopsy and prostate cancer diagnosis, follow-up

According to a new study among Medicare beneficiaries in the USA, researchers have found that 6.9 percent of men having a prostate biopsy are hospitalized within 30 days of the biopsy compared to 2.7 percent of a control group of men who did not have a prostate biopsy.

Soy isoflavones and radiation therapy: a pilot study

Soy isoflavones are known to have antioxidant and anti-inflammatory activities and to sensitize prostate cancer cells to radiation therapy.

Acute and late radiation toxicities of proton beam radiation therapy

Over the years there have been almost no publications addressing the complications of proton beam radiation therapy (PBRT) among well-defined series of prostate cancer patients. With the number of PBRT centers now growing fast, good data on the side effects of PBRT are an urgent priority.

New data on the 5-year complications of radical prostatectomy

The complex and common series of significant short- and long-term complications of radical prostatectomy (RP) — whether conducted with or without the assistance of a robot — are often not well understood by patients when they elect this form of treatment for localized prostate cancer.

Effects of prostate biopsy on voiding and erectile function

A new study from a German research group is likely to fuel concerns about some of the risks associated with prostate biopsy.

Complication rates after TRUS-guided biopsies in Canada

A new report from another group of Canadian researchers has reported a twofold to fourfold increase in the rate of hospital admissions in Ontario within 30 days of the procedure for men receiving a transrectal ultrasound-guided (TRUS-guided) prostate biopsy between 1996 and 2005.

HIFU is not necessarily as safe as suggested

We want to again make the point that treatment of localized prostate cancer with high-intensity focused ultrasound (HIFU), in the hands of inexperienced clinicians, is not necessarily as safe as some of the sales pitches might suggest. In the hands of highly experienced or highly trained HIFU practioners, with access to second- and third-generation equipment, [...]

Is RALP potentially associated with fewer complications than open surgery?

A study from the prestigious Karolinska Institute in Sweden has provided some concrete evidence that — with an appropriately high caseload and experience — robot-assisted laparoscopic prostatectomy (RALP) may, in fact, be associated with a significant reduction in surgical complications by comparison with open, radical retropubic prostatecomy (RRP).

Skeletal complications and survival of HRPC patients

It is well understood that skeletal complications are a crucial factor in the quality of life and the prognosis of patients with hormone-refractory prostate cancer (HRPC); however, their true prevalence and impact on the prognosis remain largely unknown.

The Tuesday news reports: March 31, 2009

In today’s news there are reports on: Initial diagnosis of intraductal carcinoma of the prostate An aborted trial of HIFU using the Ablatherm device Late rectal complications after prostate brachytherapy

Follow

Get every new post delivered to your Inbox.

Join 269 other followers